How These Healthcare Stocks are Performing? -- Antares Pharma, Insulet, Globus Medical, and NuVasive

Jul 27, 2016, 08:20 ET from Chelmsford Park SA

NEW YORK, July 27, 2016 /PRNewswire/ --

Ahead of today's trading session, shifts focus on the Healthcare sector, which is known for its resiliency during downturns. However, current economic conditions are making it difficult for operators to manage their resources and keep up with the increasing demands. We take a look at this morning's picks and assess their performances at the close on Tuesday, July 26, 2016: Antares Pharma Inc. (NASDAQ: ATRS), Insulet Corp. (NASDAQ: PODD), Globus Medical Inc. (NYSE: GMED), and NuVasive Inc. (NASDAQ: NUVA). Learn more about these stocks by accessing their freenotes at:

Antares Pharma 

On Tuesday, Ewing, New Jersey headquartered Antares Pharma Inc.'s stock recorded a trading volume of 322,282 shares, and ended the session 1.00% higher at $1.01. The Company's shares have gained 6.32% in the last one month. The stock is trading 0.68% above its 50-day moving average. Moreover, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have a Relative Strength Index (RSI) of 50.39.

On June 27th, 2016, Teva Pharmaceutical Industries Ltd. and Antares Pharma announced the launch of the generic equivalent to Imitrex®1 (sumatriptan succinate) injection. In the U.S. Sumatriptan injection is used to treat acute migraine with or without aura, and acute cluster headaches in adults. Approximately 36 million people in the U.S. suffer from migraine and its various characteristics. See our complete notes on ATRS at:


Billerica, Massachusettsheadquartered Insulet Corp.'s stock closed the day 1.76% higher at $34.66, and with a total volume of 233,215 shares traded. The Company's shares have advanced 21.44% in the past month and 0.55% in the previous three months. The stock is trading 12.91% and 7.57% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Insulet, which develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the U.S., have an RSI of 69.09.

On July 07th, 2016, Insulet announced plans to release its financial results for the second quarter of 2016 on August 3rd, 2016, after the close of the financial markets. In connection with the release, the company management will host a conference call on the same day at 4:30 p.m. (Eastern Time). The complimentary notes on PODD can be accessed at:

Globus Medical 

Shares in Audubon, Pennsylvania headquartered Globus Medical Inc. recorded a trading volume of 933,905 shares, which was higher than their three months average volume of 764,630 shares. The stock ended yesterday's trading session 1.65% higher at $26.43. The Company's shares have advanced 10.82% in the past month and 6.49% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 8.66% and 7.33%, respectively. Furthermore, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have an RSI of 73.70.

On July 26th, 2016, Globus Medical, announced that it has entered into an agreement to acquire Alphatec Holdings, Inc., for $80.0 million in cash, subject to certain closing adjustments. The parties expect the closing of the acquisition to occur by October 2016. As per the agreement, Globus Medical will assume Alphatec's existing international direct and distributor sales channels, which generated sales of approximately $71 million in 2015 and $15.6 million in the first quarter of 2016. Globus Medical intends to offer its own products through these sales channels, but during the transition, Globus Medical will continue to sell Alphatec products. Register for free on and access the latest notes on GMED at:


San Diego, California headquartered NuVasive Inc.'s stock finished Tuesday's session 0.05% lower at $62.00. A total volume of 740,831 shares was traded, which was above their three months average volume of 671,770 shares. The Company's shares have advanced 7.03% in the last one month, 20.02% over the previous three months, and 14.58% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.95% and 21.41%, respectively. Additionally, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 67.05.

On July 13th, 2016, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'. The research firm also revised upwards its previous target price from $55 to $74.

As per July 18th, 2016 dated notes filed with the SEC, on July 13th, 2016, NuVasive, entered into a Settlement and Patent License Agreement with Medtronic PLC and its subsidiaries with respect to the previously announced on June 30th, 2016. As per the agreement, NuVasive will pay Medtronic $45 million and the parties will release each other from inter alia, any and all past patent infringement arising from the litigation originally filed against the Company by Medtronic in 2008. Get free access to your notes on NUVA at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email RohitTuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA